A detailed history of Ray Dalio (Bridgewater Associates, LP) transactions in United Therapeutics Corp stock. As of the latest transaction made, Bridgewater Associates, LP holds 61,755 shares of UTHR stock, worth $22.5 Million. This represents 0.13% of its overall portfolio holdings.

Number of Shares
61,755
Previous 12,752 384.28%
Holding current value
$22.5 Million
Previous $4.06 Million 444.78%
% of portfolio
0.13%
Previous 0.02%

Shares

18 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

BUY
$311.04 - $363.55 $15.2 Million - $17.8 Million
49,003 Added 384.28%
61,755 $22.1 Million
Q2 2024

Aug 14, 2024

BUY
$228.26 - $319.04 $1.1 Million - $1.53 Million
4,802 Added 60.4%
12,752 $4.06 Million
Q1 2024

May 14, 2024

SELL
$210.76 - $249.51 $225,302 - $266,726
-1,069 Reduced 11.85%
7,950 $1.83 Million
Q4 2023

Feb 14, 2024

SELL
$214.88 - $256.94 $1.96 Million - $2.35 Million
-9,128 Reduced 50.3%
9,019 $1.98 Million
Q3 2023

Nov 13, 2023

SELL
$211.82 - $248.24 $4.8 Million - $5.62 Million
-22,658 Reduced 55.53%
18,147 $4.1 Million
Q2 2023

Aug 11, 2023

SELL
$205.19 - $232.99 $94,387 - $107,175
-460 Reduced 1.11%
40,805 $9.01 Million
Q1 2023

May 12, 2023

BUY
$212.99 - $276.17 $3.44 Million - $4.46 Million
16,161 Added 64.38%
41,265 $9.24 Million
Q4 2022

Feb 13, 2023

SELL
$205.95 - $280.43 $3.94 Million - $5.36 Million
-19,113 Reduced 43.23%
25,104 $6.98 Million
Q3 2022

Nov 10, 2022

SELL
$203.3 - $244.17 $2.08 Million - $2.49 Million
-10,209 Reduced 18.76%
44,217 $9.26 Million
Q2 2022

Aug 11, 2022

BUY
$174.81 - $241.14 $9.51 Million - $13.1 Million
54,426 New
54,426 $12.8 Million
Q2 2019

Aug 13, 2019

SELL
$76.06 - $120.81 $693,971 - $1.1 Million
-9,124 Closed
0 $0
Q1 2019

May 14, 2019

BUY
$107.15 - $126.84 $977,636 - $1.16 Million
9,124 New
9,124 $1.07 Million
Q4 2018

Feb 13, 2019

SELL
$101.4 - $128.73 $5.45 Million - $6.92 Million
-53,726 Closed
0 $0
Q3 2018

Nov 13, 2018

BUY
$113.81 - $129.46 $956,117 - $1.09 Million
8,401 Added 18.54%
53,726 $6.87 Million
Q2 2018

Aug 13, 2018

SELL
$101.14 - $118.31 $11.7 Million - $13.7 Million
-116,024 Reduced 71.91%
45,325 $0
Q1 2018

May 15, 2018

BUY
$107.21 - $151.94 $7.25 Million - $10.3 Million
67,626 Added 72.16%
161,349 $18.1 Million
Q4 2017

Feb 13, 2018

BUY
$118.58 - $151.28 $113,006 - $144,169
953 Added 1.03%
93,723 $13.9 Million
Q3 2017

Nov 13, 2017

BUY
$114.6 - $136.81 $10.6 Million - $12.7 Million
92,770
92,770 $10.9 Million

Others Institutions Holding UTHR

About UNITED THERAPEUTICS Corp


  • Ticker UTHR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 45,516,300
  • Market Cap $16.6B
  • Description
  • United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. Its commercial therapies include Remodulin to treat patients with pulmonary arterial hypertensio...
More about UTHR
Track Ray Dalio's Portfolio

Track Ray Dalio Portfolio

Follow Ray Dalio (Bridgewater Associates, LP) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Bridgewater Associates, LP, based on Form 13F filings with the SEC.

News

Stay updated on Bridgewater Associates, LP and Ray Dalio with notifications on news.